Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

264 Views

Poster Session: Treatment of Antimicrobial-Resistant Infections

675 - Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

The ePoster content is available to users who are logged in.<br><br>Please click the login button at the top right corner and then come back here to use this button.

Presenting Author(s)

DL

Drew Lewis, MD, MTM&H

Vice President, Clinical Development
Entasis Therapeutics
Waltham, Massachusetts, United States

Co-Author(s)

Khurram Rana, PharmD

Director, Clinical Scientist
Entasis Therapeutics
Waltham, Massachusetts, United States
GP

Gabrielle Poirier, BS

Entasis Therapeutics
Waltham, Massachusetts, United States
David Altarac, MD, MPA

Chief Medical Officer
Entasis Therapeutics
Waltham, MA, United States